M2I-1 disrupts the in vivo interaction between CDC20 and MAD2 and increases the sensitivities of cancer cell lines to anti-mitotic drugs via MCL-1s

by Jianquan Li, Nanmao Dang, Nuria Martinez-Lopez, Paul A. Jowsey, Dong Huang, Robert N. Lightowlers, Fei Gao, Jun-Yong Huang
Published 2019-06-01